Literature DB >> 21258900

Evolution of the management of colorectal cancer using integrative medicine.

Shao-Tang Li1, Pan Chi.   

Abstract

Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. In recent years, the development of new and effective management options, such as fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), total mesorectal excision (TME) and monoclonal antibody novel "targeted" therapies has led to a considerable improvement in the outcome of this disease. In China, studies on CRC using integrative medicine (IM) have made remarkable progress. We therefore review the recent developments in CRC treatment through IM and Western medicine, including research studies such as the exploitation of Chinese herbs for the disruption of the tumor cell cycle or inhibition of tumor cell proliferation, induction of tumor cell apoptosis, improvement of the immune system, and the curative effect of chemotherapy. We also examine clinical studies such as those on special prescriptions and medicines and IM in anti-cancer therapy. Particularly, we analyze the advantages and disadvantages of management with IM, and propose a suggestion for the management of colorectal cancer with IM, such as screening for effective prescriptions. We also analyze Chinese medicine, studying the pharmacologic mechanism of its anti-cancer effect, further strengthening the study of IM on CRC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258900     DOI: 10.1007/s11655-011-0610-9

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  28 in total

Review 1.  Surgical resection of liver metastases of colorectal carcinoma: short and long-term results.

Authors:  M Lorenz; E Staib-Sebler; K Hochmuth; S Heinrich; C Gog; G Vetter; A Encke; H H Müller
Journal:  Semin Oncol       Date:  2000-10       Impact factor: 4.929

2.  [Cohort study on fuzheng capsule and quxie capsule in reducing relapse and metastasis of cancer in patients with stage II and III colorectal carcinoma after operation].

Authors:  Lin Luo; Yu-fei Yang; Pei-hong Li
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2006-08

3.  Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis.

Authors:  Christian N Arnold; Ajay Goel; Hubert E Blum; C Richard Boland
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

4.  [Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis].

Authors:  Gang Xu; Wen Huang; Wei-min Zhang; Zhuo-sheng Lai; Mei-rong He; Ya-dong Wang; Ya-li Zhang
Journal:  Di Yi Jun Yi Da Xue Xue Bao       Date:  2005-01

Review 5.  Colorectal cancer: genetics of development and metastasis.

Authors:  Tetsuji Takayama; Koji Miyanishi; Tsuyoshi Hayashi; Yasushi Sato; Yoshiro Niitsu
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

Review 6.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

Review 7.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

Review 8.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

Review 9.  Does the immune system see tumors as foreign or self?

Authors:  Drew Pardoll
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 10.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Authors:  Shobha Rani Nalluri; David Chu; Roger Keresztes; Xiaolei Zhu; Shenhong Wu
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

View more
  5 in total

1.  Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway.

Authors:  Li-Hui Wei; Jiu-Mao Lin; Jian-Feng Chu; Hong-Wei Chen; Qing-Yu Li; Jun Peng
Journal:  Chin J Integr Med       Date:  2017-10-28       Impact factor: 1.978

Review 2.  Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape.

Authors:  Xue-Gang Sun; Xiao-Chang Lin; Jian-Xin Diao; Zhi-Ling Yu; Kun Li
Journal:  Chin J Integr Med       Date:  2015-11-10       Impact factor: 1.978

3.  Homeopathy and integrative medicine: keeping an open mind.

Authors:  Paolo Bellavite
Journal:  J Med Person       Date:  2014-12-17

4.  Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivo.

Authors:  Guohua Yang; Xiangwei Meng; Lili Sun; Ningning Hu; Shuang Jiang; Yuan Sheng; Zhifei Chen; Ye Zhou; Dexing Chen; Xiao Li; Ningyi Jin
Journal:  Exp Ther Med       Date:  2014-11-24       Impact factor: 2.447

5.  Efficacy of jianpi huatan granule in reducing colorectal cancer metastasis and recurrence after radical resection and adjuvant chemotherapy: Study protocol for a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Liusheng Li; Qian Qu; Ning Cui; Linlin Cai; Jianhua Zou; Jiao Wu; Tengteng Hao; Yu Wu
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.